Physician profile
Frank Addo
NPI 1679592828
$6,519.25
in general payments reported to CMS, 2019-2025
25 companies · $954 in 2025
The $954 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $158 · 2020: $56.49 · 2021: $754 · 2022: $748 · 2023: $3,046 · 2024: $804 · 2025: $954.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,820 · Travel and Lodging: $1,983.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,819.59 |
| Travel and Lodging | $1,983.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $2,503.36 | 2022-2025 | Watchman Access System, Watchman Flx |
| Novartis Pharmaceuticals Corporation | $805.36 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $688.70 | 2021-2025 | Verquvo |
| Pfizer INC. | $604.07 | 2020-2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $320.21 | 2019-2025 | Lifevest |
| Astrazeneca Pharmaceuticals LP | $203.43 | 2019-2025 | Farxiga |
| E.R. Squibb & Sons, L.L.C. | $181.61 | 2021-2025 | Camzyos, Eliquis |
| Janssen Pharmaceuticals, INC | $164.69 | 2019-2024 | Xarelto |
| Amgen INC. | $140.91 | 2022-2025 | Repatha, Repatha |
| Edwards Lifesciences Corporation | $129.39 | 2025 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Esperion Therapeutics, INC. | $126.17 | 2021-2025 | Nexletol |
| Boehringer Ingelheim Pharmaceuticals, INC. | $124.89 | 2021-2023 | Jardiance |
| Scpharmaceuticals INC. | $87.33 | 2023-2025 | |
| Inspire Medical Systems, INC. | $75.83 | 2025 | Inspire |
| Lantheus Medical Imaging, INC. | $67.73 | 2019-2020 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lexicon Pharmaceuticals, INC. | $64.44 | 2023-2024 | Inpefa |
| Bayer Healthcare Pharmaceuticals INC. | $50.47 | 2025 | |
| Sanofi-Aventis U.S. LLC | $50.08 | 2019-2024 | |
| Kiniksa Pharmaceuticals International, Plc | $23.26 | 2024 | Arcalyst |
| Glaxosmithkline, LLC. | $20.76 | 2025 | Arexvy, Shingrix |
| W. L. Gore & Associates, INC. | $19.77 | 2022 | |
| Chiesi USA, INC. | $17.06 | 2025 | Juxtapid |
| Philips North America LLC | $16.88 | 2025 | Ambulatory Monitoring & Diagnostics Undivided |
| Abbott Laboratories | $16.79 | 2025 | Thoratec Heartmate 3 Lvas Implant Kit |
| Astellas Pharma US INC | $16.06 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Frank Addo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.